Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
46.45 USD | +1.31% | -3.15% | +66.73% |
05-13 | Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab | MT |
05-13 | Merus Carcinoma Treatment Awarded US FDA's Breakthrough Therapy Designation | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.73% | 2.69B | |
+5.66% | 111B | |
+11.23% | 105B | |
-12.15% | 22.34B | |
-3.67% | 21.93B | |
-6.17% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Citigroup Adjusts Price Target on Merus to $47 From $38, Maintains Buy Rating